$OCUL reported total net revenue of $15.4 million for the third quarter of 2024. The company anticipates total net revenues for DEXTENZA to range between $62 million and $67 million for the fiscal year 2024. The SOL-1 clinical trial is expected to be fully randomized by the end of 2024, with topline data projected for the fourth quarter of 2025. As of now, $OCUL has a cash balance of $427.2 million, providing a cash runway into 2028. Additionally, active clinical trial sites are now enrolling patients directly into the SOL-R trial. Bank of America has issued a buy rating on $OCUL with a price target of $18, noting that the randomization into SOL-1 is expected to conclude by year-end, with the topline data anticipated to be a significant catalyst in 2025.